50 / 62
Primary endpoint
•
ORR
Secondary endpoints
•
DCR at 12 weeks, DoR, TTR, PFS, OS, safety
Cohort A:
Durvalumab 1500 mg +
tremelimumab 75 mg q4w
for up to 4 months, then
durvalumab 1500 mg q4w
(n=10)
Interim
analysis*
Key patient inclusion criteria
•
ED-SCLC
•
Refractory or resistant to 1L
chemotherapy
•
Life expectancy ≥8 weeks
•
No prior exposure to immunotherapy
•
WHO/ECOG PS 0–1
Bondarenko I, et al. Ann Oncol 2018;29(suppl 5):Abstr 1665PD
*Interim ORR analysis followed by expansion stage with n=20
Preliminary efficacy of durvalumab plus tremelimumab
in platinum-refractory/resistant EDSCLC from arm A of the phase II BALTIC study